Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7789]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows
Prof Peter Hillmen - St James’ University Hospital, Leeds, UK
Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows ( Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )
19 Jun 2014
LHRH analogue goserelin helps preserve fertility among women undergoing chemo...
Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA
LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer ( Dr Halle Moore - Taussig Cancer Institute, Cleveland, USA )
12 Jun 2014
Investigating anticarcinogenic compounds as an alternative to chemo
Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy
Investigating anticarcinogenic compounds as an alternative to chemo ( Dr Bernardo Bonnani - European Institute of Oncology, Milan, Italy )
6 Jun 2014
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second...
Prof Marc Peeters - University of Antwerp, Antwerp, Belgium
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )
2 Jun 2014
Summary of breaking prostate news from ASCO 2014
Prof Eleni Efstathiou and Prof Gordon McVie
Summary of breaking prostate news from ASCO 2014 ( Prof Eleni Efstathiou and Prof Gordon McVie )
2 Jun 2014
PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against...
Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US
PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US )
2 Jun 2014
Ipilimumab and nivolumab achieves long-term survival in advanced melanoma
Prof Mario Sznol - Yale Cancer Center, New Haven, USA
Ipilimumab and nivolumab achieves long-term survival in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )
2 Jun 2014
Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III...
Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands
Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma ( Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands )
2 Jun 2014
HPV-targeted adoptive T Cell therapy may provide a new personalised strategy...
Dr Christian S. Hinrichs - Center for Cancer Research, Bethesda, US
HPV-targeted adoptive T Cell therapy may provide a new personalised strategy for advanced cervical cancer ( Dr Christian S. Hinrichs - Center for Cancer Research, Bethesda, US )
2 Jun 2014
Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for...
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Comment: Adjuvant ipilimumab in high-risk melanoma
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma
Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )
2 Jun 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation